Loyal portfolio

KORTUC Inc. logo

KORTUC Inc.

Healthcare / Medical / Biomed · USA

PilotUSAINSEADSDG 3SDG 17SDG 9
Kazuyuki MatsudaS

Kazuyuki Matsuda · Seiko Kuroda

About KORTUC Inc.

KORTUC is a clinical-stage biotech developing KRC-01, a novel hydrogen peroxide-based radiosensitizer designed to unlock the full therapeutic potential of radiotherapy. Our registrational breast cancer study has completed enrollment, with pivotal data expected in 2027. We are also advancing clinical programs in cervical and rectal cancers across the U.S., Europe and Asia, with the goal of bringing KRC-01 to cancer patients globally.

Visit website

In the news

  • Oct 2

    KORTUC INC. completes enrollment in its 184-patient breast cancer trial and enrolls the first patient in its cervical cancer study.

    View on LinkedIn
  • Sep 28

    KORTUC INC. meets with cervical cancer program collaborators at ASTRO2026 to exchange perspectives on clinical development.

    View on LinkedIn
  • Sep 28

    KORTUC INC. meets with cervical cancer program collaborators at ASTRO2026 to exchange perspectives on clinical development.

    View on LinkedIn
  • Sep 22

    KORTUC INC. advances clinical programs, completing breast-cancer enrollment and initiating cervical- and rectal-cancer studies.

    View on LinkedIn
  • Sep 18

    KORTUC INC. reaches target enrollment in its registrational breast cancer trial as three global cancer programs advance.

    View on LinkedIn

Founders

  • Kazuyuki Matsuda

    Kazuyuki Matsuda

  • S

    Seiko Kuroda

Details

Stage
Pilot
Sector
Healthcare / Medical / Biomed
Country
USA
Region
USA
Source
INSEAD
UN SDGs
SDG 3SDG 17SDG 9